Group 1: Analyst Ratings - Curaleaf has received multiple analyst ratings, with ATB Cormark Capital Markets upgrading it to "outperform" on December 2nd, Alliance Global Partners maintaining a "buy" rating on December 22nd, and Zacks Research upgrading from "strong sell" to "hold" on January 1st [1] - The consensus rating for Curaleaf is "Buy," with two analysts rating it as Strong Buy, one as Buy, and one as Hold [1] Group 2: Financial Metrics - Curaleaf's market capitalization is $1.35 billion, with a P/E ratio of -6.60 and a beta of 0.71 [2][3] - The company has a quick ratio of 0.76, a current ratio of 1.52, and a debt-to-equity ratio of 1.14 [2][3] - The stock has a fifty-day simple moving average of $2.35 and a two-hundred-day simple moving average of $2.60 [2][3] Group 3: Quarterly Earnings - In its latest quarterly earnings report on February 26th, Curaleaf reported earnings per share (EPS) of ($0.05), exceeding the consensus estimate of ($0.08) by $0.03 [4] - The company generated revenue of $333.07 million for the quarter, surpassing the consensus estimate of $328.70 million [4] - Curaleaf has a negative return on equity of 23.17% and a negative net margin of 18.08% [4] Group 4: Company Overview - Curaleaf Holdings, Inc. is a leading American cannabis company involved in the cultivation, processing, and distribution of medical and adult-use cannabis products [5] - The company operates cultivation facilities, processing centers, and retail dispensaries across multiple U.S. jurisdictions, utilizing a vertically integrated model to manage its supply chain [5] - Curaleaf's product portfolio includes premium flower, vaporizer cartridges, edibles, tinctures, topicals, and concentrates [6]

Core Insights - The company achieved its first-ever full year of positive adjusted operating income, driven by a corporate restructuring program that resulted in over $20 million in annualized savings [1] - Annual free cash flow doubled to $18 million through disciplined working capital management and operational efficiencies, despite a decline in top-line performance in the fourth quarter [1] - The slowdown in the cannabis market in late 2025 was attributed to retail door saturation in key provinces like Alberta and Ontario, along with aggressive year-over-year price competition [1] Financial Performance - The company leveraged a vertical integration model to gain 20 basis points of market share in both liquor and cannabis segments, which helped offset broader industry contractions [1] - A debt-free balance sheet with over $250 million in cash allowed the company to increase capital expenditures by nearly 50%, focusing on high-performing retail banners like Wine and Beyond [1] - The consolidation of ERP systems aimed to unlock process optimization and enhance analytical capabilities, with the goal of further reducing general and administrative expenses [1] Strategic Initiatives - The company prioritized international growth and leadership in edibles following the Indiva acquisition, which contributed to a 32% revenue increase in Cannabis Operations [1]

Industry Overview - The cannabis sector is regaining investor interest after experiencing significant declines over the past two years, with federal cannabis reform discussions acting as a major catalyst for potential recovery [1][22] - Demand for cannabis is growing in both medical and adult-use markets, with several U.S. states expanding retail programs and increasing dispensary licenses, which supports long-term industry growth [2][22] Company Highlights Fluent Corp. (CNTMF) - Fluent Corp. is a vertically integrated cannabis company primarily focused on the U.S. medical cannabis market, with a strong presence in Florida, which is one of the largest medical cannabis markets in the U.S. [5][7] - The company operates approximately 30 dispensaries, mainly in Florida, and emphasizes quality products and strong patient relationships [6][7] - Fluent is investing in cultivation facilities and developing proprietary cannabis brands to differentiate itself in a crowded market, while also focusing on improving operational efficiency and reducing operating expenses [9][10] Glass House Brands Inc. (GLASF) - Glass House Brands is headquartered in California and operates cultivation, manufacturing, distribution, and retail operations, benefiting from California's status as the largest legal cannabis market in the U.S. [12][13] - The company focuses on greenhouse cultivation, which allows for more efficient production and lower costs, aiming to become one of the lowest-cost cannabis producers in the industry [13][15] - Glass House has reported improving operational performance, with revenue growth driven by increased cultivation output and a focus on reducing production costs [15][16] Verano Holdings Corp. (VRNOF) - Verano Holdings is a larger multi-state cannabis operator with operations across several major states, including Florida and Illinois, which are significant markets for cannabis [18][19] - The company operates approximately 158 dispensaries and maintains a vertically integrated model, allowing control over cultivation and production [18][19] - Verano generates significantly higher revenue than many cannabis penny stocks, with annual sales in the hundreds of millions, although it faces industry challenges such as federal prohibition and high tax burdens [20][21] Conclusion - The cannabis industry is dynamic, with regulatory developments and legalization efforts shaping its future, and as more states expand cannabis programs, demand for legal products is expected to rise [22][23] - Companies like Fluent Corp., Glass House Brands, and Verano Holdings are positioned within major cannabis markets, with their vertically integrated operations providing exposure to cultivation, manufacturing, and retail sales [23][24]

Core Insights - The U.S. marijuana industry is rapidly expanding with more states legalizing cannabis for medical and adult use, creating investment opportunities in leading marijuana stocks [1] - The top three marijuana stocks to watch in March 2026 are Trulieve Cannabis Corp. (TCNNF), Green Thumb Industries Inc. (GTBIF), and Curaleaf Holdings Inc. (CURLF), each showcasing unique strengths within the cannabis ecosystem [1][10] Trulieve Cannabis Corp. (TCNNF) - Trulieve is a major vertically integrated cannabis operator with over 150 dispensaries across high-demand states like Florida, California, and Pennsylvania [2] - The company has shown resilience in financial performance, with revenue growth and improved gross margins, while net income returned to profitability for consecutive quarters [4][6] - Trulieve's diversified model attracts investors focused on scale and brand penetration, supported by proprietary product technologies and strategic partnerships [2][4] Green Thumb Industries Inc. (GTBIF) - Green Thumb is a leading cannabis consumer packaged goods company, focusing on branded products and proprietary formulations distributed through over 20 state markets [6] - The latest financial results indicate stabilized revenue growth, particularly from branded product segments, with improved gross margins and positive EBITDA [7] - The company emphasizes innovation and strategic partnerships, enhancing its brand recognition and operational stability [6][7] Curaleaf Holdings Inc. (CURLF) - Curaleaf operates over 200 dispensaries in major cannabis markets and combines retail operations with cultivation and ancillary business segments [8] - Recent financial reports show continued revenue growth driven by product demand and improved operating efficiency, with a focus on high-growth product categories [9] - The company's diversified revenue mix and technology-enabled solutions position it as a resilient player in the cannabis sector [8][9]

Core Insights - The Canadian cannabis sector is evolving with renewed investor interest, particularly in companies with U.S. exposure as regulatory discussions in the U.S. gain momentum [1][2][5] - Canadian cannabis companies are focusing on international revenue and operational discipline due to slowed growth in the domestic market [2][3] - Strategic partnerships and brand licensing are seen as alternative paths for growth amid challenges like oversupply and U.S. federal prohibition [4][5] Industry Overview - The Canadian recreational cannabis market is mature, but growth has decelerated compared to previous years, prompting companies to seek international opportunities [2] - Global cannabis reform is progressing, with countries like Germany expanding medical programs, which may benefit Canadian producers with international infrastructure [3] Company Profiles Tilray Brands Inc. (TLRY) - Tilray is a major Canadian cannabis producer with operations in Canada, Europe, Latin America, and the U.S., offering a diverse product portfolio [6][9] - The company has a strong U.S. presence through beverage alcohol brands and strategic partnerships, although it does not own THC dispensaries [7][9] - Recent quarterly revenue exceeded $200 million, showing modest year-over-year growth, with international sales contributing significantly [10] - Despite a net loss, the company has narrowed its losses and improved gross margins through operational efficiencies [11] Canopy Growth Corporation (CGC) - Canopy Growth is a well-known cannabis company producing a variety of products, including dried flower and beverages, with a broad brand portfolio [12][15] - The company has strategic arrangements for U.S. exposure but does not operate THC dispensaries [13][15] - Canopy has undergone restructuring to reduce costs and divest non-core assets, aiming for improved financial consistency [16][18] - Recent revenue trends have been mixed, but cost controls have helped reduce operating losses [17][18] Cronos Group Inc. (CRON) - Cronos focuses on branding and product innovation, operating in Canada, Israel, and select international markets [19][22] - The company relies on wholesale distribution and partnerships rather than a large dispensary network, with limited U.S. retail exposure [20][22] - Financially, Cronos has shown gradual improvement, with recent revenue growth driven by international demand, particularly from Israeli medical sales [23][24] - The company maintains a strong cash position, providing flexibility for future expansion, although overall revenue is smaller compared to competitors [24][25]

Core Viewpoint - Cannabis stocks have underperformed over the past five years, but recent positive regulatory changes in the U.S. may present long-term growth opportunities if the marijuana market expands significantly [1] Group 1: Canopy Growth - Canopy Growth is a leading player in the Canadian cannabis market with a diverse product portfolio, including dried cannabis flower, vapes, and edibles, and has a presence in multiple countries, including the U.S. [2] - Following President Trump's executive order to classify cannabis as a Schedule III substance, Canopy Growth may have expansion opportunities in the U.S. [3] - In Q3 2026, Canopy Growth reported net revenue of $54.62 million, a slight decrease of 0.3% year-over-year, but improved its net loss per share to $0.13 from $0.81 in the previous year [3] - If Canopy Growth can capitalize on U.S. opportunities and continue to reduce losses, it could yield strong returns [4] Group 2: Tilray Brands - Tilray Brands also has a comprehensive portfolio of cannabis products and operates in several countries, including the U.S., Germany, and Portugal, and has diversified into craft brewing and hemp-based products [5] - In Q2 of its 2026 fiscal year, Tilray reported net revenue of $217.5 million, a 3% year-over-year increase, while its net loss improved to $0.41 from $0.99 in the previous year [6] - Tilray is well-positioned to take advantage of emerging opportunities in the U.S. cannabis market, which could lead to significant share price increases if successful [6]

Financial Data and Key Metrics Changes - In Q1, net revenue increased by 49% to CAD 65.3 million from CAD 42.7 million in the same prior year period, primarily due to growth in the Canadian business, integration of Motif, and higher international sales [17] - Adjusted gross profit for the quarter increased by 67% to CAD 23.9 million compared to CAD 14.3 million in Q1 last year, supported by higher revenue and efficiency gains [17][18] - Adjusted EBITDA in Q1 was CAD 5.3 million, up 273% from CAD 1.4 million in the prior year period, driven by increased scale and higher international sales [20][21] - Net income for the quarter was CAD 20 million compared to a net loss of CAD 23 million in the same prior year period, reflecting a CAD 43 million year-over-year improvement [21][22] Business Line Data and Key Metrics Changes - In Q1, international sales reached CAD 5 million, up 55% from Q1 fiscal 2025, despite a sequential decline due to a higher-than-expected proportion of flower that did not meet international specifications [12][17] - The company maintained the number one position in overall vapes with a 20.4% market share and moved to the number two position in overall pre-rolls at 7.7% [8][10] - In beverages, market share increased by 80 basis points year-over-year to 5.9%, while in concentrates, the company achieved a 15.5% category share [8][10] Market Data and Key Metrics Changes - The company holds the number one market share position in Canada with 11.3% total share in Q1 and 11.7% over the past 12 months [5][6] - In Quebec, the company moved up to the number three position with 9.9% market share for the quarter, driven by successful vape launches [7] - The company outperformed in most provinces, holding 33.1% market share in New Brunswick and 21.9% in Newfoundland [8] Company Strategy and Development Direction - The company is focused on operational execution, improving margins, and delivering to markets while balancing risk and growth opportunities in international markets [29][30] - The company aims to expand into international markets prudently while maintaining a strong focus on consumer needs and innovation [30][31] - The company is optimistic about long-term growth in the cannabis industry and its ability to compete and lead as the market matures [5] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of the BC General Employees' Union strike and increased competition in vapes and pre-rolls on market share [6][15] - The company remains confident in its ability to deliver against previously issued guidance, expecting revenue to exceed CAD 300 million for the full year [24] - Management expressed optimism about international sales growth in fiscal 2026, despite temporary issues with product specifications [12][13] Other Important Information - The company harvested over 28,000 kilograms of flower in Q1, representing a 43% year-over-year increase, driven by improved yields and ongoing refinements [10] - The company announced a proprietary breakthrough in powdery mildew resistance, allowing for quicker screening of seedlings [11] - Total cash and short-term investments at quarter end were CAD 63 million, including CAD 7.6 million of unrestricted cash [23] Q&A Session Summary Question: Near-term opportunities and prioritization of initiatives - Management emphasized operational execution and cost base improvement as short-term priorities, while focusing on international expansion for long-term growth [29][30] Question: Insight on international volumes and flower issues - Management noted stringent international flower requirements and identified core drivers of recent issues, expecting to resolve them soon [35] - The estimated impact on international revenue was about CAD 3.5 million due to out-of-spec flower [36] Question: Recovery in the Canadian market - Management confirmed recovery in BC distribution levels and acknowledged increased competition in vapes and pre-rolls, with plans for new innovations to regain market share [42][43] Question: EU GMP certification timeline - Management is working closely with regulators to address feedback and is unable to provide a specific timeline for certification [47][48] Question: Route to market in Europe - Management indicated a mixed approach for market entry, utilizing both direct sales and partnerships depending on regulations [51][53] Question: U.S. market investment strategy - Management stated that the U.S. market is currently a minor part of the business, and they are being cautious with investments due to regulatory uncertainties [55][56]

Industry Overview - The U.S. cannabis sector is evolving in early 2026, presenting both risks and opportunities for investors [1] - Regulatory uncertainty has shifted focus towards efficiency, balance sheet repair, and selective growth among operators [1][2] - Potential federal reforms could significantly reshape industry valuations, prompting investors to be more selective [1][2] Investment Focus - Traders are prioritizing companies with established market positions, improving cash flow, and scalable infrastructure [2] - Multi-state operators are expected to benefit from future regulatory changes, including federal tax treatment and banking access [2] Market Volatility - The cannabis market remains volatile, necessitating disciplined risk management [3] - Many stocks are trading below previous highs, creating opportunities for patient investors [3] - Weaker operators may face challenges if capital markets remain tight, emphasizing the importance of company selection [3] February 2026 Outlook - February 2026 is anticipated to be significant for the sector, influenced by earnings updates, regulatory news, and market sentiment [4] - Investors are looking for stocks that combine scale, brand strength, and improved financial discipline [4] Featured Companies AYR Wellness Inc. (AYRWF) - AYR Wellness is a vertically integrated operator with a growing national footprint, primarily in Florida and other states [6][8] - The company focuses on operational control across the supply chain, allowing adjustments based on market demand [9] - Recent restructuring efforts aim to strengthen liquidity and reduce financial strain, with a focus on cost control and cash flow trends [10][11] Cresco Labs Inc. (CRLBF) - Cresco Labs is a well-established multi-state operator with a strong presence in both medical and adult-use markets [12][14] - The company emphasizes brand consistency and consumer trust, with a dual approach of retail and wholesale operations [15] - Financially, Cresco generates high revenue totals, focusing on improving adjusted EBITDA and operating cash flow [16][17] Glass House Brands Inc. (GLASF) - Glass House Brands operates with a strong focus on California, utilizing large greenhouse facilities for cost-efficient production [18][20] - The company emphasizes operational efficiency and quality control through vertical integration [21] - Financial performance has been uneven due to market challenges, but increased production volumes and potential regulatory improvements could support future growth [22][23]

Core Viewpoint - The U.S. cannabis sector is evolving as 2026 begins, with multi-state operators positioned for long-term growth despite ongoing volatility creating both risks and opportunities. Investors are focusing on companies with scale and brand strength, specifically AYR Wellness, Curaleaf Holdings, and Verano Holdings [1]. AYR Wellness Inc. (AYRWF) - AYR Wellness is a vertically integrated cannabis operator with a growing national footprint, operating cultivation, manufacturing, and retail assets across several states. The company serves both medical and adult-use customers and emphasizes premium flower and derivative products [2]. - AYR has faced industry-wide challenges, with revenue growth slowing due to pricing pressure and competition. However, it continues to generate meaningful top-line sales, and gross margins remain stable compared to peers. Operating expenses are elevated, impacting profitability, but liquidity management remains a priority [4]. Curaleaf Holdings Inc. (CURLF) - Curaleaf is one of the largest cannabis companies in the U.S., with a broad footprint across many legalized states and dozens of dispensaries. The company serves both medical and adult-use consumers, offering a wide range of branded products [5][7]. - Financially, Curaleaf demonstrates relative strength with high revenue, although year-over-year growth has slowed. Gross margins remain competitive, and operating cash flow has improved, supporting balance sheet flexibility. Cost controls have helped protect margins, and international operations contribute to incremental growth [9]. Verano Holdings Corp. (VRNOF) - Verano Holdings operates dispensaries across multiple high-value states and has a strong retail focus. The company prioritizes disciplined expansion in markets with strong demand fundamentals and emphasizes premium branding and customer experience [10]. - Despite generating significant revenue, Verano faces profitability challenges due to pricing compression affecting margins. Elevated operating expenses and interest costs have led to persistent net losses, but cash reserves support near-term operations. Management is focused on improving efficiency and reducing long-term expenses [12]. Overall Market Outlook - As January 2026 unfolds, the U.S. cannabis market is in transition, with AYR Wellness, Curaleaf, and Verano each offering unique strengths and sizable retail footprints. Financial discipline is critical, and investors should closely monitor margins, cash flow, and balance sheets as market conditions may improve over time [14].

Core Viewpoint - Cronos Group Inc. is acquiring CanAdelaar B.V. for an up-front cash consideration of US$67.0 million, plus additional cash earnouts based on normalized EBITDA for 2026 and 2027, positioning Cronos as the market leader in the Netherlands' adult-use cannabis market [1][2]. Transaction Overview - The acquisition involves an up-front payment of €57.5 million (US$67.0 million), representing approximately 1.4 times CanAdelaar's last twelve months (LTM) revenue and 2.4 times LTM EBITDA [1][8]. - The transaction is expected to close in early 2026, pending regulatory approvals in the Netherlands [9]. Strategic Rationale - The acquisition is seen as financially compelling and strategically important for establishing a footprint in Europe and leveraging investments in borderless products [2][12]. - CanAdelaar is the largest cannabis company in the Netherlands' adult-use cannabis pilot program, known as the Wietexperiment, which is designed to create a regulated cannabis supply chain [3][4]. Market Context - The Wietexperiment was enacted in 2020 and officially launched in April 2025, allowing for the sale of cannabis in ten municipalities, with the potential for expansion [3][12]. - CanAdelaar has a current cultivation yield of approximately 20,000 kg of dried flower annually and is the only industrial-scale greenhouse cultivator in the Wietexperiment [6][12]. Financial Performance - CanAdelaar's revenue is projected to grow from US$17.7 million in 2024 to US$47.3 million for the twelve months ending September 30, 2025 [6]. - EBITDA is expected to increase from US$8.0 million in 2024 to US$28.2 million for the twelve months ending September 30, 2025 [7]. Competitive Positioning - CanAdelaar holds the leading market share within the Wietexperiment, with active sales to nearly all 72 coffee shops involved in the program [5][12]. - The regulatory framework of the Wietexperiment is designed to promote responsible adult use, potentially serving as a model for other countries [12].